2
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Vomiting
13
Nausea
13
Neoplasms
8
Hematologic Neoplasms
5
Anorexia
4
Cachexia
3
Breast Neoplasms
3
Weight Loss
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Multiple Myeloma
2
Lung Neoplasms
2
Advanced Cancer
2
Testicular Neoplasms
1
Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy
1
Sedentary Behavior
1
Radiation Injuries
1
Prosthesis Failure
1
Postoperative Nausea and Vomiting
1
Pain
1
Opioid-Related Disorders
1
Nutrition Disorders
1
Neoplasms, Plasma Cell
1
Neoplasms, Germ Cell and Embryonal
1
Muscular Atrophy
1
Multiple Endocrine Neoplasia Type 1
1
Lymphoma
1
Insulin Resistance
1
Hyperlipidemias
1
Hyperglycemia
1
Interventions
ostarine
3
rimabotulinumtoxinB
1
Standard of Care
1
Olanzapine
1
Exercise
1
Enteral Nutrition
1
Electric Stimulation
1
Eicosapentaenoic Acid
1
Diet Therapy
1
Cyproheptadine
1
Creatine
1
Carnitine
1
Botulinum Toxins, Type A
1
Acetylcysteine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Muscular Atrophy
×
Olanzapine
×
Clear all
NCT06175273
2025-09-18
POINT
University of Kentucky
Phase 2/3
Completed
19 enrolled